Mukesh Nandave – författare

This book integrates the latest advancements in biomedical science related to metabolic syndrome and microbiome research. It comprehensively covers a broad range of topics including composition and function of the gut microbiota in metabolic syndrome, mechanisms linking the gut microbiome to metabolic syndrome, dietary interventions, pharmacological approaches, exercise, lifestyle modifications, psychosocial factors, role of the gut microbiome in obesity and insulin resistance, and clinical applications and translational perspectives.  

Despite significant research on metabolic syndrome, its risk factors, therapeutic interventions and the role of microbiome, there is still lack of recent updates and massive efforts are required to update the information on these topics with special emphasis on potential interventions targeting the gut microbiome to mitigate metabolic syndrome risk. This book focuses on leveraging the intricate relationship between the microbiome, gut health, and metabolic syndrome, including dysbiosis, inflammation, impaired gut barrier function, mechanisms through which the gut microbiome influences metabolic syndrome including host-microbiota interactions, microbial metabolites, and immune modulation to develop innovative interventions aimed at improving overall health outcomes. The purpose of this research is to explore microbiome-based interventions that can positively influence gut ecology and mitigate the risk factors associated with metabolic syndrome. By understanding how specific dietary interventions, probiotics, prebiotics, and other microbiome-targeted therapies can modulate the gut microbiome, this work aims to develop effective strategies for optimizing gut health and metabolic function.

Through interdisciplinary collaboration and cutting-edge research methodologies, this work strives to pave the way for personalized approaches to healthcare that prioritize the microbiome as a key determinant of overall health and well-being. The principal audience for this book comprises of pharmacologists, microbiologists, clinical pharmacists, and toxicologists.

The book explores the world of medicinal plants through a groundbreaking and comprehensive book. It delves into high-throughput technologies and multi-omics approaches to unlock the untapped potential of endophytic fungi, revealing novel bioactive compounds. It further talks about the diverse biodiversity and ethnopharmacological knowledge, unravelling the molecular intricacies of secondary metabolites under varying ecological conditions. This gives insights into medicinal plant research, offering cutting-edge insights into genome-based barcoding, nanotechnology, and functional genomics for revolutionary drug discoveries. From proteomic and epigenomic analysis to big data exploration, this book presents a holistic view of medicinal plants'' potential and discusses the latest advancements in micropropagation, agronomical approaches, and genome editing, paving the way for transformative medicines and healthcare breakthroughs.

It serves as a great resource for academicians, researchers, and pharmacologists.

This book delves into diverse facets and applications of medicinal plants. It discusses the metabolic, transcriptomic, and genomic intricacies of medicinal plants, shedding light on their chemical compositions, genetic makeup, and regulatory mechanisms. It includes a chapter on nanotechnology, investigating the influence of nanoparticles on medicinal plants. Subsequent chapters explore functional genomics and genome editing, showcasing innovative approaches to modifying plant genetics. It also discusses plant-associated microorganisms in the microbiome and endophytic fungi. Furthermore, the book addresses the critical issues of genetic diversity, agrotechnology for sustainable production, intellectual property rights, and the impact of various stresses on medicinal plants.

This book serves as a valuable resource for researchers, educators, and students of pharmacology, offering a comprehensive understanding of medicinal plants and their evolving role in science and medicine.

This book is a comprehensive coverage of the ubiquitin-proteasome system and its involvement in cancer progression, and the application of PROTACs in different types of cancer treatment. The book discusses a unique perspective and comprehensive knowledge of the potential of PROTACs to transform cancer therapies. It provides an overview of the history, mechanisms, chemistry, design considerations, and different technologies involved in PROTACs. Additionally, it explains the ubiquitin-proteasome system, its impact on various diseases, and the principles and mechanisms of UPS. The book also describes the chemistry and design aspects of PROTACs and their role in various types of cancers. Finally, it covers the pharmaceutics aspect of formulation design, global requirements, and toxicological aspects of PROTACs. This book is targeted at cancer researchers, medical oncologists, bioinformatics, computational biologists, pharmacologists, medicinal chemists, formulation scientists, regulatory authorities, and policy makers.

This book delves into the various aspects of the renin-angiotensin-aldosterone system (RAAS) and its role in cardiovascular disorders. It explores the use of anti-hypertensive agents, with a focus on (ACE) angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs). The chapters cover topics such as the preferred use of ACE inhibitors over ARBs in high-risk patients, the impact of these agents on insulin resistance, their role in acute heart failure and peripheral artery disease, and their immunomodulatory activity in hypertensive patients. Additionally, the book examines the role of ACE inhibitors and ARBs in COVID-19 patients and provides insights into recent trends in managing hypertension through RAAS inhibition.

It serves as a valuable resource for researchers, clinicians, and healthcare professionals involved in the field of cardiovascular medicine.

The book delves into the development and therapeutic potential of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of diabetes and cardiovascular diseases. It explores their mechanism of action, cardiovascular benefits, and role in primary and secondary protection from renal and cardiovascular diseases. The book also highlights their emerging opportunities in the management of myocardial infarction, diabetic cardiomyopathy, and congestive heart failure. It provides a comprehensive review of preclinical and clinical information on the cardiovascular advantages of SGLT2 inhibitors. Additionally, the book explores selective drugs and their effects on cardiovascular events, mortality, and safety outcomes in individuals with type 2 diabetes.

The book is a valuable resource for researchers, healthcare professionals, and individuals interested in the field of SGLT2 inhibitors and their impact on diabetes and cardiovascular health.

The book explores the field of pharmacovigilance, its historical context, along with its critical role in ensuring the safety of medications across the world. From its foundational principles to cutting-edge advancements and future challenges, this book provides a thorough understanding of the field''s intricacies. The book begins by establishing the fundamentals of pharmacovigilance, emphasizing its significance in monitoring, detecting, assessing, and preventing adverse drug reactions (ADRs) that occur during the use of medications. Delving into the history of pharmacovigilance and regulatory actions, the book traces the evolution of the field, highlighting significant milestones and the establishment of regulatory frameworks that govern medication safety. It explores the pivotal role of regulatory authorities in developing guidelines, regulations, and policies to safeguard public health. A significant aspect covered in the book is the processing of ADRs, providing insights into the steps involved in handling and evaluating ADR reports.  The book also addresses specialized areas within pharmacovigilance, including vaccine safety surveillance, herbovigilance (monitoring the safety of herbal medicines), materiovigilance (monitoring the safety of medical devices), and hemovigilance (ensuring the safety of blood products). Additionally, the book explores the role of pharmacogenetics in pharmacovigilance, highlighting how genetic factors influence individual responses to medications and how this knowledge can be integrated into safety monitoring and risk assessment. This book also covers databases used in pharmacovigilance across the globe, aggregate reporting and pharmacovigilance systems in EU and non-EU countries, and the role of artificial intelligence.

Finally, it emphasizes the need for continuous improvement, vigilance, and proactive measures to adapt to the changing healthcare landscape and address emerging safety concerns. The book serves as acomprehensive guide for healthcare professionals, researchers, regulators, and policymakers involved in pharmacovigilance.